MASHINIi

Nanobiotix S.A..

NBTX.US | Research and experimental development on natural sciences and engineering

Nanobiotix S.A. is a late-stage clinical biotechnology company focused on developing innovative, nanotechnology-driven approaches to cancer treatment. Their lead product, NBTXR3, is a first-in-class radioenhancer designed to amplify the efficacy of radiotherapy in various solid tumors. The company's...Show More

Ethical Profile

Mixed.

Nanobiotix S.A.'s ethical standing presents a mixed picture, with limited public information available across many key areas. As a clinical-stage biotechnology company, reports suggest Nanobiotix likely conducts animal testing for preclinical research, with specific studies mentioning the use of mice to test cancer treatments. Critics point to a lack of evidence that the company has implemented alternative testing methods or a formal policy against animal testing, despite a broader industry trend towards reducing such practices. For most other ethical categories, there is insufficient public data to form a comprehensive assessment.

Value Scores

Better Health for All0
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals0
-100100
No War, No Weapons0
-100100
Planet-Friendly Business-20
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

0

No relevant evidence was found in the provided articles to assess NBTX.US against any of the 'Better Health for All' KPIs. The articles either contained no data,

1
were about a different company (Unisync Corp.),
2
or were unavailable.
3

Fair Money & Economic Opportunity

0

No evidence available to assess Nanobiotix S.A. on Fair Money & Economic Opportunity.

Fair Pay & Worker Respect

0

No specific, concrete data points for Nanobiotix S.A. (NBTX.US) were found across any of the provided articles for the KPIs under the 'Fair Pay & Worker Respect' value. Several articles explicitly state a lack of data for relevant metrics such as living wage, pay equity, collective bargaining, safety, worker engagement, turnover, labor violations, insecure contracts, and health insurance coverage for NBTX.US.

1
Information regarding CEO compensation for NBTX.US was provided,
2
but not the median employee compensation, which is necessary to calculate the CEO-to-median-pay ratio.
3
Information regarding these KPIs for other pharmaceutical companies or as general industry trends was not applied to NBTX.US.

Fair Trade & Ethical Sourcing

0

The provided articles, including a preliminary prospectus, a registration statement, and a code of business conduct and ethics, do not contain specific, quantifiable information related to fair trade and ethical sourcing. No data is available regarding fair-trade certification share, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical clauses in supplier contracts, share of spend on high-risk materials, or supplier diversity spend.

1

Honest & Fair Business

0

No specific, quantitative evidence was found in the provided articles for any of the KPIs related to Honest & Fair Business. While the company is noted to be publicly traded and files various reports (e.g., Form 6-K, S-8, SCHEDULE 13G, EFFECT) with the SEC as required, the articles do not contain data on regulatory fines, transparency index scores, whistleblower policies, financial restatements, audit coverage, ESG controversy scores, complaint resolution times, board conflict-free percentages, anti-corruption policies, or third-party verification of ethical claims.

1

Kind to Animals

0

No specific, concrete data points were found in the provided articles to assess Nanobiotix S.A. against any of the 'Kind to Animals' KPIs. While articles describe the company's preclinical research involving animal models (mice),

1
they do not provide information regarding the volume of animals used, specific animal testing policies, the extent of alternative testing methods employed, humane certifications for animal operations, or investments in animal-free technologies by Nanobiotix S.A. The articles primarily focus on the scientific outcomes of their research or general industry trends and regulatory actions, rather than the company's specific animal welfare practices or commitments.

No War, No Weapons

0

Nanobiotix S.A. is a biotechnology company focused on developing cancer treatments, with its lead product NBTXR3 being a radioenhancer for solid tumors.

1
The provided articles detail the company's clinical trials, financial performance, and regulatory approvals for medical applications. No information was found regarding any involvement in arms manufacturing, military contracts, dual-use technologies with military applications, sales to embargoed regimes, peacebuilding investments, or any other activities related to the 'No War, No Weapons' ethical value. Therefore, all KPIs for this value must be omitted due to a lack of explicit evidence.

Planet-Friendly Business

-20

The company's R&D practices are in compliance with relevant national and EU regulations, and operating procedures have been duly audited by Competent Authorities.

1
The NANOBIOTIX (EGFF) project was implemented in line with EIB Environmental and Social Standards.
2
An Environmental Impact Assessment (EIA) was not required for this project.
3

Respect for Cultures & Communities

0

No evidence available to assess Nanobiotix S.A. on Respect for Cultures & Communities.

Safe & Smart Tech

0

No evidence available to assess Nanobiotix S.A. on Safe & Smart Tech.

Zero Waste & Sustainable Products

0

No evidence available to assess Nanobiotix S.A. on Zero Waste & Sustainable Products.

Own Nanobiotix S.A.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.